Skip to main content
RemeGen Co., Ltd. logo

RemeGen Co., Ltd. — Investor Relations & Filings

Ticker · 9995 ISIN · CNE1000048G6 LEI · 300300M9HCX4TFAD4I10 HKEX Manufacturing
Open in API
Filings indexed 1,624 across all filing types
Latest filing 2024-10-17 Regulatory Filings
Country CN China
Listing HKEX 9995

About RemeGen Co., Ltd.

http://www.remegen.com

RemeGen Co., Ltd. is a biopharmaceutical company dedicated to the discovery, development, production, and commercialization of innovative biological drugs. The company focuses on creating first-in-class and best-in-class therapeutics to address significant unmet clinical needs, particularly in the critical therapeutic areas of autoimmune diseases, oncology, and ophthalmology. RemeGen utilizes proprietary technology platforms capable of discovering, screening, and developing new molecules and efficiently optimizing production processes. Its pipeline includes a series of innovative biologics, such as Telitacicept, and features 8 clinical pipelines, over 40 clinical trials, and more than 600 patent applications, demonstrating a strong commitment to R&D and innovation in biopharmaceuticals.

Recent filings

Filing Released Lang Actions
DATE OF BOARD MEETING
Regulatory Filings Classification · 95% confidence The document is an announcement from the Board of Directors of RemeGen Co., Ltd. stating the date of a board meeting to consider and approve the unaudited third quarterly results for the nine months ended September 30, 2024. The document does not contain the actual financial results or detailed financial data but only announces the upcoming meeting and the intention to publish the results. The document length is short (1531 characters) and it explicitly states the meeting will consider and approve the results and their publication. This fits the pattern of a Regulatory Filing (RNS) as it is an announcement related to regulatory compliance and upcoming report publication, not the report itself. Therefore, the correct classification is Regulatory Filings (RNS).
2024-10-17 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2024
Regulatory Filings Classification · 95% confidence The document is titled 'Monthly Return for Equity Issuer and Hong Kong Depositary Receipts listed under Chapter 19B of the Exchange Listing Rules on Movements in Securities' for the month ended 30 September 2024. It details movements in authorised/registered share capital, issued shares, treasury shares, share options, warrants, convertibles, and other agreements related to share issuance. The document is a regulatory submission to the Hong Kong Exchanges and Clearing Limited, providing detailed monthly updates on share capital and share movements. It is not an annual or interim financial report, earnings release, or management discussion. It is also not a proxy statement, voting result, or remuneration report. The document is a regulatory filing reporting share capital and share movement information as required by exchange rules. Therefore, the most appropriate classification is Regulatory Filings (RNS). The document length (8195 characters) and detailed content confirm it is a substantive regulatory filing rather than a brief announcement or report publication notice.
2024-10-07 English
Monthly Return of Equity Issuer on Movement in Securities for the month ended 30 September 2024
Major Shareholding Notification Classification · 95% confidence The document is a monthly return report detailing movements in authorised/registered share capital, issued shares, and treasury shares for Overseas Chinese Town (Asia) Holdings Limited. It includes specific data on share capital balances, share options, warrants, convertibles, and confirmations related to share movements. The document is structured as a regulatory submission to the Hong Kong Exchanges and Clearing Limited, consistent with ongoing compliance reporting requirements rather than a financial report or announcement of a capital change event. It does not announce new share issues or capital changes but reports on the status and movements of shares for the month ended 30 September 2024. Given the detailed nature of share capital and share movement data, this fits the category of Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership levels or share capital movements under regulatory rules. The document is not a simple announcement or a report publication notice, nor is it a full financial report or earnings release. Therefore, the best classification is MRQ with high confidence.
2024-10-02 English
2024 Interim Report
Interim / Quarterly Report Classification · 100% confidence The document is titled '2024 Interim Report' for RemeGen Co., Ltd. It contains detailed financial summaries, management discussion and analysis, and interim condensed consolidated financial statements such as profit or loss, comprehensive income, financial position, changes in equity, and cash flows. The presence of an Independent Review Report further supports that this is a formal interim financial report. The document length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement. The content and structure align with the characteristics of an Interim / Quarterly Report, which provides comprehensive financial data for a period shorter than a full fiscal year (in this case, six months ended June 30, 2024). H1 2024
2024-09-25 English
CHANGE OF DATE OF EXTRAORDINARY GENERAL MEETING, RECORD DATE AND BOOK CLOSURE DATE
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the change of date for an Extraordinary General Meeting (EGM), including changes to the record date and book closure date. It references the original EGM notice and related documents but does not contain the actual meeting materials, voting results, or financial data. The document is short (4142 characters) and serves to inform shareholders about scheduling changes and procedural details for the upcoming EGM. It explicitly states that other documents such as the EGM Notice, circular, and proxy form remain unchanged and valid, and no revised versions will be published. This fits the pattern of a Regulatory Filing (RNS) as it is a general regulatory announcement and does not constitute the meeting materials themselves or voting results. Therefore, the appropriate classification is Regulatory Filings (RNS).
2024-09-16 English
Interim Report 2024
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Interim Report 2024' and contains detailed financial data and management discussion and analysis for the six months ended 30 June 2024. It includes comprehensive financial results, business review, segment performance, and financial review with actual figures and analysis. The length is substantial (15,000 characters), and it is not merely an announcement or certification. The content matches the definition of an Interim / Quarterly Report (IR), which is a comprehensive financial report for a period shorter than a full fiscal year containing substantive financial data and analysis. H1 2024
2024-09-12 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.